Recently, the first early phase clinical trial organized and managed by START Shanghai has been successfully launched at the FUSCC-START Phase I clinical trial center. Patient recruiting process has been started.
The drug is an innovative anti-cancer biological agent. It is thought that this drug can specifically target and function on certain cancer cell lines. During this Phase I clinical trial, drug safety and efficacy will be carefully evaluated at the FUSCC-START clinical trial center. An efficient and constructive cooperation has been seen between START Shanghai and the sponsor from the very beginning of the project. This first clinical trial also marks the advanced FUSCC-START center being officially put into use for START’s research project.